首页 | 本学科首页   官方微博 | 高级检索  
     

影响药物毒性神经病理学评价质量的主要因素
引用本文:屈哲,林志,吕建军,霍桂桃,杨艳伟,张頔,张硕,霍艳,耿兴超,王雪,李波. 影响药物毒性神经病理学评价质量的主要因素[J]. 现代药物与临床, 2017, 40(9): 1348-1354
作者姓名:屈哲  林志  吕建军  霍桂桃  杨艳伟  张頔  张硕  霍艳  耿兴超  王雪  李波
作者单位:中国食品药品检定研究院 国家药物安全评价监测中心、药物非临床安全评价研究北京市重点实验室, 北京 100176;中国食品药品检定研究院 国家药物安全评价监测中心、药物非临床安全评价研究北京市重点实验室, 北京 100176;中国食品药品检定研究院 国家药物安全评价监测中心、药物非临床安全评价研究北京市重点实验室, 北京 100176;中国食品药品检定研究院 国家药物安全评价监测中心、药物非临床安全评价研究北京市重点实验室, 北京 100176;中国食品药品检定研究院 国家药物安全评价监测中心、药物非临床安全评价研究北京市重点实验室, 北京 100176;中国食品药品检定研究院 国家药物安全评价监测中心、药物非临床安全评价研究北京市重点实验室, 北京 100176;中国食品药品检定研究院 国家药物安全评价监测中心、药物非临床安全评价研究北京市重点实验室, 北京 100176;中国食品药品检定研究院 国家药物安全评价监测中心、药物非临床安全评价研究北京市重点实验室, 北京 100176;中国食品药品检定研究院 国家药物安全评价监测中心、药物非临床安全评价研究北京市重点实验室, 北京 100176;中国食品药品检定研究院 国家药物安全评价监测中心、药物非临床安全评价研究北京市重点实验室, 北京 100176;中国食品药品检定研究院, 北京 100050
基金项目:十二五国家科技重大专项(2015ZX09501004-002,2015ZX09501007-004)
摘    要:神经毒性是许多药物或化合物常见的毒副作用。在新药研发早期要进行神经毒性筛选。对于可能通过血脑屏障影响神经系统的小分子药物或疫苗类的生物制品在临床前安全性评价中要进行非人灵长类动物的神经毒性评价。毒性病理学或神经病理学评价是临床前药物神经毒性评价的金标准。针对影响药物毒性神经病理学评价质量的几个主要因素,包括神经病理学评价的一般策略、最佳的评价时机、特殊的神经组织屏障系统、神经组织病理制片中的取材方法以及人工假象对神经病理学诊断的干扰,进行详细的解析,以期为我国神经毒性评价指导原则的制定和药物非临床神经毒性研究提供参考。

关 键 词:毒理学  神经病理学  小分子药物  临床前安全性评价  神经毒性  新药研发
收稿时间:2017-06-12

Major factors influencing quality of neuropathology evaluation of drug toxicology
QU Zhe,LIN Zhi,L,#; Jian-jun,HUO Gui-tao,YANG Yan-wei,ZHANG Di,ZHANG Shuo,HUO Yan,GENG Xing-chao,WANG Xue and LI Bo. Major factors influencing quality of neuropathology evaluation of drug toxicology[J]. Drugs & Clinic, 2017, 40(9): 1348-1354
Authors:QU Zhe,LIN Zhi,L&#   Jian-jun,HUO Gui-tao,YANG Yan-wei,ZHANG Di,ZHANG Shuo,HUO Yan,GENG Xing-chao,WANG Xue  LI Bo
Affiliation:Beijing Key Laboratory for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China;Beijing Key Laboratory for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China;Beijing Key Laboratory for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China;Beijing Key Laboratory for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China;Beijing Key Laboratory for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China;Beijing Key Laboratory for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China;Beijing Key Laboratory for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China;Beijing Key Laboratory for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China;Beijing Key Laboratory for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China;Beijing Key Laboratory for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China;National Institutes for Food and Drug Control, Beijing 100050, China
Abstract:Neurotoxicity is one common adverse effect caused by many drugs or compounds. In the early phase of new drug development, it is necessary to screen for neurotoxicants. Neurotoxicity studies in nonhuman primates (NHP) are used to evaluate the neurotoxicity of small-molecule drugs or vaccines that may affect the nervous system across the blood-brain barrier during preclinical safety assessment. Toxicologic pathological evaluation or neuropathological examination is the "gold standard" for the evaluation of drug neurotoxicity in preclinical drug safety studies. In this paper, the majory factors influencing the quality of neuropathology evaluation in toxicology, including the general strategy of neuropathology evaluation, the optimal timing of evaluation, the specific blood-brain barrier in the nervous system, the method of sampling in the histopathology of nerve tissue, and the interference of artificial artifacts in diagnosis of neuropathology, were detailly analyzed in order to provide a reference for setting guidelines of neurotoxicity risk assessment in China and pathologists and toxicologists engaged in nonclinical neurotoxicity studies.
Keywords:toxicology  neuropathology  small-molecule drugs  preclinical safety evaluation  neurotoxicity  new drug development
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号